PanTher Completes Phase 1b Dose Escalation in Non-Metastatic Pancreatic Cancer and Appoints Tim Clackson to Board of Directors
PanTher Therapeutics Advances PTM-101 with Phase 1b Dose Escalation Completion in Pancreatic Cancer and Appoints Oncology Veteran Tim Clackson to Board PanTher Therapeutics, a clinical-stage biotechnology company developing implant-based localized…
Canopy Growth Reintroduces Tweed Brand in Germany with New MTL Cannabis Lineup, First Post-Acquisition Global Launch
Canopy Growth Relaunches Tweed Brand in Germany and Expands Medical Cannabis Portfolio Following MTL Acquisition Canopy Growth Corporation has announced a major strategic milestone in its international expansion strategy with…
Meiji Seika Pharma Invests in GHIC Global Health Security Fund
Meiji Seika Pharma Invests in Global Health Security Fund to Advance Pandemic Preparedness and Infectious Disease Innovation Meiji Seika Pharma Co., Ltd., one of Japan’s leading pharmaceutical companies with a…
Merck’s Calderasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant Non-Small Cell Lung Cancer
Merck’s Investigational KRAS Inhibitor Calderasib Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutated Lung Cancer Merck, known as MSD outside the United States and Canada, has announced a significant…
BeOne Medicines Highlights 78-Month BRUKINSA Data Demonstrating Sustained Disease Control in CLL at ASCO 2026
BeOne Medicines Showcases Long-Term BRUKINSA Success and Next-Generation CLL Treatment Advances at ASCO 2026 BeOne Medicines Ltd., a global oncology company dedicated to developing innovative cancer therapies, is presenting extensive…
CorWave Secures ISO 13485 Certification, Advancing Commercialization of Cardiac Assist Devices
CorWave Achieves ISO 13485 Certification, Advancing Commercialization Plans for Innovative Heart Failure Devices CorWave, a clinical-stage medical technology company focused on developing next-generation cardiac assist devices, has announced a significant…
IMFINZI Approved in U.S. as First Immunotherapy Combination for High-Risk NMIBC
IMFINZI® (durvalumab) Becomes First Approved Immunotherapy Combination in the U.S. for Patients with BCG-Naïve High-Risk Non-Muscle-Invasive Bladder Cancer AstraZeneca has secured a significant new regulatory milestone for its immunotherapy IMFINZI…
Pfizer and Innovent Biologics Forge Global Oncology Partnership to Advance Next-Generation Cancer Therapies
Pfizer and Innovent Biologics Forge Major Global Oncology Partnership to Advance Next-Generation Cancer Medicines Pfizer Inc. and Innovent Biologics have announced a landmark strategic global licensing and collaboration agreement aimed…
ReST Therapeutics Announces FDA Acceptance of IND Application for RST-101 in Early PTSD Treatment
ReST Therapeutics Receives FDA IND Clearance for PTSD Therapy RST-101 ReST Therapeutics announced that the U.S. Food and Drug Administration has accepted the company’s Investigational New Drug (IND) application for…
Otsuka Pharmaceutical Presents New Phase 3 Centanafadine ADHD Data at the ASCP Annual Meeting
Otsuka Pharmaceutical Development & Commercialization Presents New Phase 3 Centanafadine Analyses Highlighting Broader ADHD Symptom Improvements Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization unveiled new post hoc…
Draig Therapeutics Showcases Positive Phase 1 DT-101 Data at ASCP Annual Meeting
Draig Therapeutics Highlights Positive Phase 1 DT-101 Results at ASCP Annual Meeting American Society for Clinical Psychopharmacology served as the stage for new clinical and translational data from Draig Therapeutics,…
BeOne Medicines Reports Phase 3 HERIZON-GEA Results Published in NEJM and Featured at ASCO 2026
BeOne Medicines Reports Phase 3 HERIZON-GEA Results Published in NEJM and Featured at ASCO 2026 BeOne Medicines has announced the publication and upcoming presentation of significant new clinical data from…